Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):367-71. doi: 10.1097/QAI.0b013e3182910121.

Abstract

Activation of coagulation pathways may contribute to risk for non-AIDS-related conditions among HIV-positive patients. Tissue factor (TF)-dependent procoagulant activity on circulating microparticles (MP-TF) in the plasma of 163 HIV-positive participants, both untreated and treated, with viral suppression was measured. MP-TF activity was 39% lower among treated versus untreated participants (P < 0.001), which persisted in adjusted models (-36%, P = 0.03). Among treated participants, MP-TF activity correlated modestly with D-dimer (r = 0.24, P = 0.01), von Willebrand factor (r = 0.36, P < 0.001), and interleukin-6 (r = 0.20, P = 0.04) levels. Future research should focus on mechanisms driving residual functional TF activity and whether these alterations have clinical consequences for non-AIDS-defining complications.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Blood Coagulation / drug effects*
  • Blood Coagulation Tests
  • C-Reactive Protein / analysis
  • Cell-Derived Microparticles
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • Humans
  • Inflammation / immunology*
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Thromboplastin / analysis
  • Thromboplastin / metabolism*
  • von Willebrand Factor / analysis

Substances

  • Anti-HIV Agents
  • Interleukin-6
  • von Willebrand Factor
  • C-Reactive Protein
  • Thromboplastin